RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Last trade$1.04
Day change+$0.0851 (+8.91%)
Day range$0.97 – $1.05
Volume393,482
Market cap$46M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$45.84M
Price / earnings
—
Price / book
4.94×
Price / sales
16.51×
EV / sales
12.76×
EV / EBITDA
-2.61×
Profitability
Earnings per share
-$0.27
Return on assets
-104.69%
Return on equity
-140.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.65×
Quick ratio
5.49×
Cash ratio
4.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RNXT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.07M
$909K
$563K
$238K
$266K
$422K
$197K
$43K
Cost of revenue
$188K
$143K
$84K
$28K
$53K
$152K
$94K
$0
Gross profit
$878K
$766K
$479K
$210K
$213K
$270K
$103K
$43K
Selling, general and administrative
$2.87M
$2.92M
$2.72M
$2.23M
$1.73M
$1.52M
$1.57M
$1.1M
Research and development
$1.24M
$1.2M
$1.23M
$1.5M
$1.69M
$1.43M
$1.64M
$1.58M
Total operating expenses
$4.11M
$4.12M
$3.95M
$3.73M
$3.41M
$2.95M
$3.21M
$2.68M
Operating income
-$3.24M
-$3.35M
-$3.47M
-$3.52M
-$3.2M
-$2.68M
-$3.11M
-$2.63M
Interest expense
$76K
$90K
$0
$0
$113K
$133K
$0
$0
Income before taxes
-$3.65M
-$2.91M
-$3.52M
-$2.94M
-$2.91M
-$2.9M
-$2.42M
-$2.88M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.65M
-$2.91M
-$3.52M
-$2.94M
-$2.91M
-$2.9M
-$2.42M
-$2.88M
Net income attributable to common shareholders
-$3.65M
-$2.91M
-$3.52M
-$2.94M
-$2.91M
-$2.9M
-$2.42M
-$2.88M
EBITDA
-$3.23M
-$3.34M
-$3.47M
-$3.52M
-$3.2M
-$2.68M
-$3.11M
-$2.63M
Basic earnings per share
-$0.08
-$0.06
-$0.09
-$0.08
-$0.08
-$0.08
-$0.08
-$0.11
Diluted earnings per share
-$0.08
-$0.06
-$0.09
-$0.08
-$0.08
-$0.08
-$0.08
-$0.11
Recent news
Company coverage with links to the original publishers.
RenovoRx (RNXT) reported a quarterly loss of $0.07 per share, missing the consensus estimate of $0.05 loss by 40%, though revenues of $1.07 million exceeded expectations by 1.52%. The stock has gained 55.9% year-to-date, outperforming the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
RenovoRx announced publication of PK/PD data from its Phase III TIGeR-PaC clinical trial showing that its TAMP platform achieved approximately 51% tumor-site drug extraction with decreased systemic exposure when delivering intra-arterial gemcitabine. The study demonstrated a statistically significant correlation between drug metabolite levels and tumor marker reduction, supporting the platform's targeted delivery mechanism. The company achieved full enrollment in the trial with completion expected in H1 2027 and topline data in H2 2027.
RenovoRx, Inc. (Nasdaq: RNXT) has been recognized as the #10 most innovative medical device company by Fast Company for 2026. The company generated $1.1 million in RenovoCath sales during its first full year of commercialization in 2025, with growing adoption at major cancer centers. The Phase III TIGeR-PaC trial for intra-arterial gemcitabine is on track for enrollment completion by mid-2026, with final data expected in 2027.
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.